BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease
Masuo Ohno,Evgeny A. Sametsky,Linda H. Younkin,Holly Oakley,Steven G. Younkin,Martin Citron,Robert Vassar,John F. Disterhoft +7 more
596
TL;DR: It is shown that BACE1 null mice engineered to overexpress human APP (BACE1(-/-).Tg2576(+)) are rescued from Abeta-dependent hippocampal memory deficits, demonstrating that lower Abeta levels are beneficial for AD-associated memory impairments and validating Bace1 as a therapeutic target for AD.
read more
About: This article is published in Neuron. The article was published on 08 Jan 2004. and is currently open access. The article focuses on the topics: BACE1-AS & Knockout mouse.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation.
Holly Oakley,Sarah L. Cole,Sreemathi Logan,Erika Maus,Pei Shao,Jeffery Craft,Angela L. Guillozet-Bongaarts,Masuo Ohno,John F. Disterhoft,Linda J. Van Eldik,Robert W. Berry,Robert Vassar +11 more
TL;DR: 5XFAD mice rapidly recapitulate major features of AD amyloid pathology and may be useful models of intraneuronal Aβ42-induced neurodegeneration and amyloids plaque formation.
3.2K
Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of β-secretase
Mohammad Ali Faghihi,Mohammad Ali Faghihi,Farzaneh Modarresi,Ahmad M. Khalil,Douglas E. Wood,Barbara G. Sahagan,Todd E. Morgan,Caleb E. Finch,Georges St. Laurent,Georges St. Laurent,Paul J. Kenny,Claes Wahlestedt +11 more
TL;DR: It is reported that a long noncoding RNA is directly implicated in the increased abundance of Aβ 1–42 in Alzheimer's disease.
APP processing in Alzheimer's disease
TL;DR: Current knowledge of APP processing regulation as well as the patho/physiological functions of APP and its metabolites are reviewed.
The secretases: enzymes with therapeutic potential in Alzheimer disease
TL;DR: Secretase inhibitors are likely to be the first small-molecule therapies aimed at AD modification that will be fully tested in the clinic and will have enormous consequences for further drug development efforts for AD and possibly other neurodegenerative conditions.
Protein aggregation diseases: pathogenicity and therapeutic perspectives
Adriano Aguzzi,Tracy O'Connor +1 more
TL;DR: It is now clear that ordered aggregation of pathogenic proteins does not only occur in the extracellular space, but in the cytoplasm and nucleus as well, indicating that many other diseases may also qualify as amyloidoses.
756
References
The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease
Marcus A. Westerman,Deirdre Cooper-Blacketer,Ami Mariash,Linda Kotilinek,Takeshi Kawarabayashi,Linda H. Younkin,George A. Carlson,Steven G. Younkin,Karen H. Ashe +8 more
TL;DR: It is suggested that A βinsol is a surrogate marker for small assemblies of Aβ that disrupt cognition and occur as intermediates during Aβinsol formation, and they are the first descriptive in vivo data supporting their role in impairing memory.
730
The Neuroendocrine Basis of Social Recognition
TL;DR: The social recognition deficits seen in oxytocin knockout mice have now been demonstrated in both males and females, as well as in female estrogen receptor knockout mice.
574
Long-term memory underlying hippocampus-dependent social recognition in mice.
TL;DR: It is suggested that group‐housed mice show social memory for a familiar juvenile when tested immediately, 30 min, 24 h, 3 days, and 7 days after a single 2‐min‐long interaction, and that it is a powerful paradigm to investigate hippocampal learning and memory.
510
Amyloid-β immunotherapy for Alzheimer's disease : the end of the beginning
TL;DR: Immunotherapy represents one of the first tests of the amyloid hypothesis in the clinic, and is an evolving approach to the treatment of Alzheimer's disease that offers a genuine opportunity to modify disease progression.
491
Aβ-Generating Enzymes: Recent Advances in β- and γ-Secretase Research
Robert Vassar,Martin Citron +1 more
TL;DR: BACE and BACE2 share 64% amino acid A is generated by endoproteolytic processing of the acid similarity and both have a C-terminal transmem-large type I transmembrane protein, amyloid precursor brane domain this paper.
313
Related Papers (5)
Robert Vassar,Brian D. Bennett,Safura Babu-Khan,Steve Kahn,Elizabeth A. Mendiaz,Paul Denis,David B. Teplow,Sandra Ross,Patricia Amarante,Richard Loeloff,Yi Luo,Seth Fisher,Janis Fuller,Steven P. Edenson,Jackson Lile,Mark A. Jarosinski,Anja Leona Biere,Eileen Curran,Teresa L. Burgess,Jean Claude Louis,Frank H. Collins,James J. S. Treanor,Gary Rogers,Martin Citron +23 more
Sukanto Sinha,John P. Anderson,Robin Barbour,Guriqbal S. Basi,Russell J. Caccavello,David Davis,Minhtam Doan,Harry F. Dovey,Normand Frigon,Jin Hong,Kirsten L. Jacobson-Croak,Nancy Jewett,Pamela S. Keim,J. Knops,Ivan Lieberburg,Michael Power,Hua Tan,Gwen Tatsuno,Jay Tung,Dale Schenk,Peter Seubert,Susanna Suomensaari,Shuwen Wang,Donald A. Walker,Jun Zhao,Lisa McConlogue,Varghese John +26 more